Literature DB >> 16222045

Effects of recombinant human activated protein C in human models of endotoxin administration.

Edward Abraham1.   

Abstract

Alterations in the generation of activated protein C (APC) as well as in the interactions of APC with the endothelial protein C receptor are present in severe sepsis and acute lung injury. Administration of recombinant human activated protein C (rhAPC) improves the survival of critically ill patients with sepsis, but the mechanisms by which rhAPC produces benefit are not well defined. Human models of systemic and pulmonary endotoxin exposure may provide important insights into the mechanisms of action of rhAPC in critical illness. In volunteers given systemic endotoxin, rhAPC had minimal effects on physiologic parameters, including blood pressure, markers of inflammation, and measures of sepsis-induced coagulopathy. In contrast, in the setting of pulmonary endotoxin exposure, rhAPC decreased neutrophil migration into the airspaces and also diminished neutrophil chemotaxis. Administration of rhAPC did not affect other parameters of neutrophil function, including kinase activation, production of proinflammatory cytokines, or apoptosis. Such results indicate that the effects of rhAPC in inhibiting the infiltration of neutrophils into the lungs and other inflammatory sites may contribute to its beneficial effects in sepsis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222045      PMCID: PMC2713322          DOI: 10.1513/pats.200501-004AC

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  54 in total

1.  Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties.

Authors:  M A Matthay
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

2.  Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.

Authors:  B White; M Schmidt; C Murphy; W Livingstone; D O'Toole; M Lawler; L O'Neill; D Kelleher; H P Schwarz; O P Smith
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

3.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

Review 4.  Recombinant human activated protein C in severe sepsis.

Authors:  Henry J Mann
Journal:  Am J Health Syst Pharm       Date:  2002-02-15       Impact factor: 2.637

5.  Local inflammatory responses following bronchial endotoxin instillation in humans.

Authors:  N P O'Grady; H L Preas; J Pugin; C Fiuza; M Tropea; D Reda; S M Banks; A F Suffredini
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

6.  Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.

Authors:  K Hirose; K Okajima; Y Taoka; M Uchiba; H Tagami; K Nakano; J Utoh; H Okabe; N Kitamura
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

7.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

8.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis.

Authors:  S N Faust; M Levin; O B Harrison; R D Goldin; M S Lockhart; S Kondaveeti; Z Laszik; C T Esmon; R S Heyderman
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

Review 9.  Role of coagulation inhibitors in inflammation.

Authors:  C T Esmon
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

10.  Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury.

Authors:  E Abraham; A Carmody; R Shenkar; J Arcaroli
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-12       Impact factor: 5.464

View more
  13 in total

1.  Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency.

Authors:  Angelina J Lay; Deborah Donahue; Meng-Ju Tsai; Francis J Castellino
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

2.  Consensus development for healthcare professionals.

Authors:  Bory Kea; Benjamin Chih-An Sun
Journal:  Intern Emerg Med       Date:  2014-11-28       Impact factor: 3.397

3.  Protein C concentrate controls leukocyte recruitment during inflammation and improves survival during endotoxemia after efficient in vivo activation.

Authors:  David Frommhold; Julia Tschada; Natascha Braach; Kirsten Buschmann; Axel Doerner; Johanna Pflaum; Marie-Sophie Stahl; Hongjie Wang; Lutz Koch; Markus Sperandio; Angelika Bierhaus; Berend Isermann; Johannes Poeschl
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

4.  Extracellular histones inhibit efferocytosis.

Authors:  Arnaud Friggeri; Sami Banerjee; Na Xie; Huachun Cui; Andressa De Freitas; Mourad Zerfaoui; Hervé Dupont; Edward Abraham; Gang Liu
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

5.  Inhaled activated protein C protects mice from ventilator-induced lung injury.

Authors:  Nikolaos A Maniatis; Eleftheria Letsiou; Stylianos E Orfanos; Matina Kardara; Ioanna Dimopoulou; Georgios Nakos; Marilena E Lekka; Charalambos Roussos; Apostolos Armaganidis; Anastasia Kotanidou
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

6.  Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1.

Authors:  Reto A Schuepbach; Clemens Feistritzer; José A Fernández; John H Griffin; Matthias Riewald
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

Review 7.  Transfusion-related acute lung injury (TRALI): current concepts and misconceptions.

Authors:  Christopher C Silliman; Yoke Lin Fung; J Bradley Ball; Samina Y Khan
Journal:  Blood Rev       Date:  2009-08-20       Impact factor: 8.250

8.  Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model.

Authors:  Marguerite R Kelher; Tomhiko Masuno; Ernest E Moore; Sagar Damle; Xianzhong Meng; Yong Song; Xiayuan Liang; Jerry Niedzinski; Steven S Geier; Samina Y Khan; Fabia Gamboni-Robertson; Christopher C Silliman
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

9.  Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.

Authors:  Bi-Sen Ding; Nankang Hong; Melpo Christofidou-Solomidou; Claudia Gottstein; Steven M Albelda; Douglas B Cines; Aron B Fisher; Vladimir R Muzykantov
Journal:  Am J Respir Crit Care Med       Date:  2009-04-02       Impact factor: 21.405

10.  Activated protein C has a protective effect against myocardial I/R injury by improvement of endothelial function and activation of AKT1.

Authors:  Yoshito Maehata; Shigeru Miyagawa; Yoshiki Sawa
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.